Table 2.

Univariate analyses for DFS and OS

DFSOS
CovariateHR (95% CI)PHR (95% CI)P
Conditioning regimen
90YIT-R-BEAM1.001.00
 R-BEAM1.08 (0.57–2.06)0.821.20 (0.54–2.66)0.65
Age1.03 (1.00–1.06)0.101.03 (0.99–1.07)0.18
Sex
 Male1.001.00
 Female1.11 (0.60–2.05)0.751.04 (0.49–2.20)0.92
Disease status at transplant
 PR1.001.00
 CR0.77 (0.41–1.47)0.430.80 (0.36–2.71)0.57
 SD1.91 (0.57–6.40)0.303.03 (0.87–10.57)0.08
Number of prior chemotherapies
 Total chemotherapies1.51 (1.05–2.18)0.031.54 (0.99–2.40)0.05
 ≤31.001.00
 >32.20 (1.10–4.39)0.033.02 (1.05–8.74)0.04
LDH level at transplant
 Normal1.001.00
 Elevated2.20 (1.10–4.39)0.032.21 (0.97–5.03)0.06
Beta2-microglobulin level
 ≤21.001.00
 >21.75 (0.92–3.36)0.092.34 (1.03–5.31)0.04
Histologic subtype
 GCB1.001.00
 Non-GCB1.04 (0.45–2.41)0.921.32 (0.49–3.58)0.58
 PMBL0.80 (0.22–2.95)0.730.78 (0.16–3.87)0.76
 Transformed0.65 (0.27–1.56)0.330.66 (0.22–1.97)0.46
Relapse from induction (de novo histology)
 <1 year1.001.00
 >1 year0.75 (0.35–1.59)0.450.98 (0.39–2.44)0.97
Salvage therapy pretransplant
 ICE/IE1.001.00
 AP1.13 (0.55–2.31)0.741.15 (0.48–2.78)0.75
 Other1.40 (0.64–3.07)0.401.50 (0.60–3.76)0.39
IPI score at transplant
 01.001.00
 >03.14 (1.69–5.86)<0.0013.31 (1.57–6.95)<0.001
PET status at transplant
 Negative1.001.00
 Positive3.40 (1.52–7.63)<0.0015.59 (2.26–13.9)<0.001
Amount of CD34-positive cells infused0.88 (0.78–1.00)0.060.87 (0.74–1.02)0.09
  • Abbreviations: LDH, lactate dehydrogenase; GCB, germinal center B-cell-like; PMBL, primary mediastinal large B-cell lymphoma; IPI, International Prognostic Index; PET, positron emission tomography; ICE, ifosfamide, carboplatin, and etoposide; IE, ifosfamide and etoposide; AP, high-dose cytarabine and cisplatin.